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Objective: The increasing prevalence of type 2 diabetes (T2D) and associated morbidity and mortality emphasizes the need for a more complete
understanding of the mechanisms mediating glucose homeostasis to accelerate the identification of new medications. Recent reports indicate
that the obesity medication lorcaserin, a 5-hydroxytryptamine (5-HT, serotonin) 2C receptor (5-HT2CR) agonist, improves glycemic control in
association with weight loss in obese patients with T2D. Here we evaluate whether lorcaserin has an effect on glycemia without body weight loss
and how this effect is achieved.
Methods: Murine models of common and genetic T2D were utilized to probe the direct effect of lorcaserin on glycemic control.
Results: Lorcaserin dose-dependently improves glycemic control in mouse models of T2D in the absence of reductions in food intake or body
weight. Examining the mechanism of this effect, we reveal a necessary and sufficient neurochemical mediator of lorcaserin’s glucoregulatory
effects, brain pro-opiomelanocortin (POMC) peptides. To clarify further lorcaserin’s therapeutic brain circuit, we examined the receptor target of
POMC peptides. We demonstrate that lorcaserin requires functional melanocortin4 receptors on cholinergic preganglionic neurons (MC4RChAT) to
exert its effects on glucose homeostasis. In contrast, MC4RChAT signaling did not impact lorcaserin’s effects on feeding, indicating a divergence in
the neurocircuitry underpinning lorcaserin’s therapeutic glycemic and anorectic effects. Hyperinsulinemic-euglycemic clamp studies reveal that
lorcaserin reduces hepatic glucose production, increases glucose disposal and improves insulin sensitivity.
Conclusions: These data suggest that lorcaserin’s action within the brain represents a mechanistically novel treatment for T2D: findings of
significance to a prevalent global disease.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The maintenance of physiologically appropriate levels of glucose is
paramount to health and survival. Type 2 diabetes (T2D) is a disease in
which insulin fails to provide the normal tight control of blood glucose
concentration. The increased global prevalence of T2D underscores
the necessity for a more complete understanding of the mechanisms
underlying glucose homeostasis to facilitate the identification of new
medications. Current frontline T2D medications act at peripheral tis-
sues to potentiate insulin release, insulin action and/or alter glucose
absorption and excretion [1]. Here we investigate the therapeutic po-
tential of targeting the brain for T2D treatment given the growing body
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5-hydroxytryptamine (5-HT, serotonin) is required for appropriate
energy balance; however, its role in glucoregulation is less clear.
Capitalizing on the tight relationship between 5-HT and food intake,
medications augmenting the bioavailability of 5-HT were prescribed in
the 1990s and 2000s to improve obesity, but were withdrawn from
clinical use due to off target effects [10,11]. Subsequent studies
revealed that 5-HT obesity medications primarily elicit therapeutic
effects through activation of the 5-HT2C receptor (5-HT2CR) subtype
influencing the activity of pro-opiomelanocortin (POMC) neurons
(POMC5-HT2CR) within the brain [12e18]. Likewise, genetic manipu-
lation of 5-HT2CR expression exclusively within POMC neurons in-
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[5,18]. The clinical potential of 5-HT2CRs for obesity treatment was
realized in the summer of 2013 with the release of the small molecule
5-HT2CR agonist lorcaserin (BELVIQ, Eisai Inc) in the USA. However,
given that genetic dysfunction in 5-HT2CRs are associated with T2D in
mouse and man alike [4,19], we considered whether 5-HT2CRs have a
direct glucoregulatory function. Recent reports indicate that lorcaserin
also improves glycemic control in obese patients with T2D, but this
was in association with weight loss [20e23]. Preclinical compounds
with agonist properties at the 5-HT2CRs, such as m-chlor-
ophenylpiperazine (mCPP) improve glycemic control without altering
energy balance or body weight [24]. Whether lorcaserin also has
glycemic effects that may be achieved in the absence of weight loss
has not been determined. Here we take advantage of a genetic
approach in mice to evaluate whether brain 5-HT2CRs have a direct
effect on insulin sensitivity and if so, how this effect is achieved.
2. MATERIALS AND METHODS
2.1. Mice
5-HT2CR
CRE mice were crossed with ROSA26-stop-enhanced yellow
fluorescent protein (YFP) (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J;
Jackson Laboratory) mice to create a reporter 5-HT2CR
CRE:YFP line as
previously described [16]. Rosa26YFP mice have a loxP-flanked STOP
sequence followed by a Yellow fluorescent protein (YFP) gene inserted
into the Gt (ROSA)26Sor locus. Intercrossing with 5-HT2CR
CRE mice
removes the STOP sequence and YFP is visualized in 5-HT2CR
CRE
expressing cells. 5-HT2CR
CREmice were also crossedwith PomcNEOmice
[3] to generate wild type (WT), 5-HT2CR
CRE, ARC PomcNULL (PomcNEO),
and restoredPomc specifically in 5-HT2CR expressing cells (Pomc
5-HT2CR)
littermates as previously described [16]. loxTBMc4r (Jackson Labs) and
ChATCRE mice were crossed to generate WT, Mc4rNULL, ChATCRE and
loxTBMc4r mice with Mc4rs restored exclusively in cholinergic neurons
of the IML and DMV (Mc4rChAT) as previously described [25]. WT control
littermates and C57BL/6J mice (Jackson Labs) were fed 60%-fat diet
(HFD; Test Diet, 58Y1) from 3 weeks of age. All other genotypes were fed
chow throughout. All mice were maintained on a 12:12 lightedark cycle
(lights on at 0700) with ad libitum access to chow or HFD diet and water
unless otherwise stated. All experiments were in accordance guidelines
and approvals of the U.K. Animals (Scientific Procedures) Act 1986.
2.2. Drugs
Drugs were prepared in sterile saline and administered intraperito-
neally (IP). Lorcaserin (LGM Pharmaceuticals) was administered at
2.5e10 mg/kg.
2.3. Glycemic tolerance tests
At the onset of the light cycle, food was removed for 6 h to normalize
endogenous glucose levels, with the exception of the lorcaserin dose-
response glucose tolerance test (GTT; Figure 1A), in which mice were
fasted overnight during the dark cycle. Lorcaserin’s effects on glucose,
insulin, or pyruvate tolerance were assessed via pretreatment with
saline or lorcaserin prior to glucose (1 g/kg IP), insulin (0.5 U/kg IP), or
pyruvate (1.5 g/kg, IP) bolus, and blood was sampled from tail vein
immediately prior to lorcaserin/saline treatment, immediately prior to
glucose, insulin, or pyruvate bolus, and 15, 30, 45, 60, and 90 min
following bolus administration. Blood glucose was analyzed using an
AlphaTRAK glucometer (Abbott Animal Health).
2.4. Food intake
Mice were individually housed for 1 week prior to experimentation and
during this time received habituation scruffing and IP injection ofMOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elsevier GmbH. This is
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45 min prior to the onset of the dark cycle (lights on/off 0700/1900),
and food was removed. At the onset of the dark cycle, food was
returned and intake was measured at 1, 3, and 6 h later. Studies were
performed using a within-subjects experimental design, with a mini-
mum of a 3 day treatment-free period.
2.5. Insulin secretion
To measure insulin secretion, an insulin modified frequently sampled
intravenous glucose tolerance test was used. Specifically, DIO male
mice were fed 60% fat diet (Test Diet, 58Y1) from weaning to 12 weeks
and underwent surgical placement of arterial and venous catheters at
12 weeks as previously described [7,8]. Four days later, mice were
injected with saline or lorcaserin (10 mg/kg, IP) 45 min prior to delivery
of glucose (0.75 g/kg over 30 s) via venous catheter. Nine minutes after
delivery of glucose, 0.1 U/Kg rapid acting insulin was given. Blood was
sampled from freely-moving mice via arterial catheter after glucose
bolus and assayed for whole blood glucose (10, 0, 1, 2, 4, 6, 8, 12,
14, 16, 18, 20, 25, 30, 45, and 60 min) and plasma insulin (0, 1, 2, 4,
6, 10, 12, 16, 20, 30, and 60 min) by RIA (Linco). Blood loss was
minimized by intravenous infusion of heparinized blood from donor
littermates. Acute phase insulin secretion was calculated as the area
under the insulin curve from 0 to 4 min. Insulin sensitivity and glucose
effectiveness were also modeled using the minimal model [26].
2.6. Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic-euglycemic clamps were conducted as previously
described [27]. Animals were anesthetized by a combination of
6.25 mg/kg acetylpromazine, 6.25 mg/kg midazolam, and 0.31 mg/
kg fentanyl, IP. An infusion needle was placed into the tail vein and D-
[3H] glucose (specific activity: 10e20 Ci (370e740 GBq)/mmol) was
infused at a rate of 0.006 MBq/min for 60 min to achieve steady-state
levels. Thereafter, insulin (Actrapid; Novo Nordisk) was infused at a
constant rate of 0.09 mU/min after a bolus dose of 3.3 mU and D-[3H]-
glucose was continued at a rate of 0.006 MBq/min. A variable infusion
of 12.5% D-glucose was used to maintain blood glucose at eugly-
cemic (basal) levels. Blood glucose was measured with an AlphaTRAK
glucometer (Abbott Animal Health) every 5e10 min from superficial
tail vein and glucose infusion adjusted accordingly. After 50 min from
the start of the insulin infusion, [14C]-2-Deoxy-glucose-phosphate
(Specific Activity: 250e350 mCi (9.25e13.0 GBq)/mmol, IV) was
administered to assess tissue-specific glucose uptake. Steady state
was reached after 90 min and blood samples were taken at 10 min
intervals over 30 min to determine steady-state levels of [3H]-glucose.
Mice were killed by cervical dislocation and organs were removed and
frozen. Hematocrit was measured at baseline and after the clamp (no
significant changes were observed between each genotype and their
littermate controls, data not shown). To measure plasma [3H]-
glucose, proteins were precipitated with trichloroacetic acid (final
concentration 10%), centrifuged and supernatant dried and re-
suspended in water. The samples were counted using scintillation
counting (Hidex Scintilation counter, LabLogic). Tissue samples were
homogenized (w5e10% wet wt/vol, depending on tissue) in 0.5%
percholic acid, centrifuged, supernatants neutralized, and [14C]-2-
Deoxy-glucose-phosphate precipitated using BaOH/ZnSO4. The
glucose turnover rate (mmol/min) was calculated under steady-state
clamp conditions as the rate of tracer infusion (dpm/min) divided by
the plasma specific activity of [3H] glucose (dpm/mmol). The hyper-
insulinemic hepatic glucose production was calculated as the differ-
ence between the tracer-derived rate of glucose appearance and the
glucose infusion rate.an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 1093
Figure 1: Lorcaserin improves glucose and insulin tolerance in mouse model of common DIO T2D. (A) Pretreatment with lorcaserin (5.0 and 10.0 mg/kg, IP) improves
glucose tolerance (GTT; glucose 1.0 g/kg, IP) compared to saline in 12 h dark cycle fasted male DIO mice (n ¼ 9). (B) Pretreatment with lorcaserin (5.0 and 10.0 mg/kg, IP)
improves insulin tolerance (ITT; 0.75 U/kg, IP) compared to saline in 6 h light cycle fasted male DIO mice (n ¼ 8). (C) 5-HT2CRCRE line intercrossed with a Rosa26YFP line to visualize
5-HT2CR
CRE expressing cells. (D) Bilateral distribution of 5-HT2CRs (GFP-IR) by ARC bregma level (1.46 to 2.30 mm from bregma) in 5-HT2CRCRE:YFP male and female mice
(n ¼ 7). (E) Coronal image of GFP immunoreactivity (IR) in 5-HT2CRCRE:YFP male mouse at the level of the arcuate nucleus of the hypothalamus (ARC). (FeG) Dual-IHC revealed that
lorcaserin (7 mg/kg, IP) significantly increases marker for neuronal activity cFOS-IR (red) within ARC 5-HT2CRs (GFP-IR; green; co-expressed yellow) compared with saline treatment
in 5-HT2CR
CRE:YFP male and female mice (n ¼ 6/treatment). (H) Approximately 40% of POMC-IR neurons (red) co-express 5-HT2CR (GFP-IR; green; co-expressed yellow) in 5-
HT2CR
CRE:YFP male and female mice (n ¼ 6). White box in F, G, and H indicates magnified area; white arrows indicate dual-IHC cells. Scale bar in E, 200 mm. Scale bar in F
left panel, 100 mm also applies to G and H; F right panel 50 mm also applies to G and H right panels. *p < 0.05, **p < 0.01, ***p < 0.001, lorcaserin versus saline treatment.
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2.7. Immunohistochemistry (IHC)
IHC was performed using standard methods and as previously
described [16]. For mice treated with lorcaserin (7 mg/kg, IP) or saline
(IP) for cFOS and GFP analysis, the perfusion procedure occurred
90 min after treatment. Briefly, under deep terminal pentobarbital
anesthesia, mice were transcardially perfused with phosphate buff-
ered saline (PBS) followed by 4% paraformaldehyde (PFA). Brains
were extracted, post-fixed in 4% PFA at 4 C, cryoprotected in 30%
sucrose at 4 C and then sectioned coronally on a freezing sliding
microtome at 25 mm (Bright solid state freezer series 8000, Bright
Instruments). Tissue was processed for single- or dual-IHC using
published methods [16] with the following antibodies: rabbit anti-
Pomc primary antibody (1:1,000; H-029-30, Phoenix Pharmaceuti-
cals, Burlingame, CA USA) and an Alexa Fluor 594 donkey anti-rabbit
secondary antibody (1:500, A-2127, ThermoFisher Scientific); rabbit
anti-c-fos primary antibody (1:300, sc-52, Santa Cruz) followed by
Alexa Fluor 594 donkey anti-rabbit secondary antibody (1:500, A-
2127, ThermoFisher Scientific); and chicken anti-GFP primary anti-
body (1:800, ab101863, Abcam) followed by Alexa Fluor 488 donkey
anti-chicken secondary antibody (1:800, 703-545-155, Jackson
ImmunoResearch). Sections were mounted onto microscope slides
and coverslipped in an aqueous mounting medium (Vectastain; Vector
Laboratories). Slides were imaged on an AXIOSKOP2 (Zeiss) micro-
scope. For single- and dual-IHC expression, the boundaries of the
arcuate nucleus of the hypothalamus (ARC) were defined using
neuroanatomical landmarks and the Mouse Brain Atlas [28] and
analyzed 1.46 to 2.18 from Bregma.
2.8. Statistics
Data were analyzed with t-test or One-way, Two-way or Repeated
Measures ANOVA followed by Tukey’s or Bonferroni post hoc tests. For
all analyses, significance was assigned at p < 0.05. Data are pre-
sented as mean  SEM.
3. RESULTS
3.1. Lorcaserin directly improves glucose and insulin tolerance
To investigate whether 5-HT2CR agonist and obesity medication lor-
caserin has effects on glycemic control that may be dissociated from
food intake and body weight effects, WT mice were fed a 60% fat diet
for at least 12 weeks to produce a mouse model of T2D. Next, using a
within-subjects experimental design, mice were administered a single
treatment of saline or lorcaserin (2.5, 5.0 or 10.0 mg/kg, IP) 45 min
prior to a glucose tolerance test (GTT; 1 g/kg glucose, IP). Lorcaserin
produced a dose-dependent improvement in glucose tolerance, with 5
and 10 mg/kg significantly improving glucose tolerance compared to
saline (F3, 14 ¼ 11.32, p ¼ 0.005; Figure 1A). Lorcaserin (5.0 and
10.0 mg/kg, IP) also significantly improved insulin sensitivity as
measured with an insulin tolerance test (ITT; 0.75 U/kg insulin, IP) in
another cohort of DIO WT mice using a within-subjects experimental
design (F3,19 ¼ 7.08, p ¼ 0.002; Figure 1B). These data indicate that
lorcaserin significantly augments glycemic control in a mouse model of
T2D.
We next considered the anatomical localization of 5-HT2CRs performing
this glucoregulatory function. 5-HT2CRs are expressed in numerous
brain regions, including the ARC [29]. To facilitate visualization of 5-
HT2CRs within the ARC, a 5-HT2CR
CRE line intercrossed with a
B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J (Rosa26YFP) line was used
(Figure 1C). Using IHC, 5-HT2CR
CRE:YPF expression was mapped within
the ARC, which revealed that 5-HT2CRs are expressed throughout the
rostral to caudal extent of the ARC (Figure 1D,E). 5-HT2CR
CRE:YPF miceMOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comtreated with lorcaserin (7 mg/kg; Figure 1G) showed a significant in-
crease in a marker for neuronal activity c-Fos immunoreactivity (IR)
within ARC GFP-IR cells (15.1  1.7% of GFP-IR cells co-expressed
FOS-IR) compared to saline treatment (5.2  1.0% of GFP-IR cells
co-expressed FOS-IR; t (11) ¼ 8.41, p < 0.0001; Figure 1F). These
data suggest that doses of lorcaserin that improve glycemic control
influence the activity of a subset of ARC 5-HT2CR-expressing cells. We
next evaluated the neurochemical phenotype of ARC 5-HT2CR-
expressing cells. Consistent with previous reports [16,30], we
observed approximately 40% of POMC-IR neurons express 5-HT2CRs
(GFP-IR) (Figure 1H).
Taken together, these data provide evidence for a new glucoregulatory
target (5-HT2CRs) that has immediate translational relevance through
the use of a medication already in clinical use for obesity treatment, the
5-HT2CR agonist lorcaserin.
3.2. POMCARC:5-HT2CR is sufficient to perform lorcaserin’s
glucoregulatory function
Given that 5-HT2CRs are anatomically positioned to influence multiple
neurochemically defined cell types within the CNS, we next sought to
evaluate the specific contribution of POMCARC peptides to the glucor-
egulatory effects of lorcaserin. A previous report genetically manipu-
lating 5-HT2CR expression indicates that 5-HT2CRs co-expressed with
POMC neurons is sufficient to mediate preclinical 5-HT2CR agonist’s
glycemic effects in mice [5]. However, the neurochemical mediator
expressed within these neurons has not been established. We spe-
cifically investigated whether POMCARC peptides are a neurochemical
communicator of the therapeutic effect of lorcaserin. To selectively
manipulate POMCARC, we utilized a reversible ARC Pomc knockout
model (PomcNEO) crossed with a 5-HT2CR
CRE line to restore Pomc
expression specifically within 5-HT2CRs expressing (Pomc
5-HT2CR)
neurons in the ARC (Figure 2A). As expected, PomcNEO mice had no
detectable hypothalamic POMC-IR, whereas POMC-IR was restored by
40% in Pomc5-HT2CR mice (F3, 12 ¼ 12.91, p ¼ 0.0005; Figure 2B,C).
Functionally, genetic inactivation of PomcARC promotes insulin resis-
tance, but normal glucose levels, primarily by increasing glycosuria in
PomcNEO mice [31]. The hyperinsulinemia phenotype is normalized by
the restoration of Pomc in the subset of cells expressing 5-HT2CRs in
Pomc5-HT2CR mice, indicating that Pomc synthesized in 5-HT2CR cells is
sufficient to mediate POMC’s effects on insulin sensitivity [16]. We
therefore hypothesized that lorcaserin improves insulin sensitivity
without altering energy homeostasis or body weight via influencing the
release of POMCARC peptides (Figure 2E), and without functional
POMCARC, lorcaserin’s glycemic effects would not be achieved.
To address this hypothesis, we employed a dose of lorcaserin (4 mg/
kg, IP) that was not sufficient to decrease food intake in DIO WT mice (t
(12) ¼ 0.41, p ¼ 0.66; Figure 2D) or body weight (t (13) ¼ 0.12,
p ¼ 0.46; Figure S1) and used this dose for glucose and insulin
tolerance tests using a within-subjects experimental design. Lorca-
serin (4 mg/kg, IP) significantly improved glucose tolerance in both DIO
PomcWT (treatment F1, 108 ¼ 28.61, p ¼ 0.0001; Figure 2F;
Figure S2A) and 5-HT2CR
CRE control mice (treatment F1, 87 ¼ 13.02,
p¼ 0.0005; Figure 2G; Figure S2B); this effect was abolished in POMC
deficient PomcNEO mice (treatment F1, 70¼ 0.05, p¼ 0.82; Figure 2H;
Figure S2C) but restored in Pomc5-HT2CR mice (treatment F1,
108 ¼ 27.41, p ¼ 0.0001; Figure 2I; Figure S2D). In a separate cohort
of mice, we observed that lorcaserin (4 mg/kg, IP) also significantly
improved insulin tolerance in PomcWT DIO (treatment F1, 140 ¼ 42.04,
p ¼ 0.0001; Figure 2J; Figure S2E) and 5-HT2CRCRE control mice
(treatment F1, 126 ¼ 22.40, p ¼ 0.0001; Figure 2K; Figure S2F); this
effect was absent PomcNEO mice (treatment F1, 119 ¼ 0.31, p ¼ 0.57;an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 1095
Figure 2: ARC Pomc5-HT2CR is sufficient to perform lorcaserin’s glucoregulatory function. (A) A reversible ARC Pomc knock-out model (PomcNEO) was intercrossed with a 5-
HT2CR
CRE line to restore Pomc expression specifically within 5-HT2CRs expressing (Pomc
5-HT2CR) neurons. (B) Representative images and (C) quantification of average bilateral
Pomc-derived peptide immunoreactive (IR) neurons in the ARC (1.46, 1.58, 1.7, 1.82, 1.94 2.06 and 2.18 mm from bregma) in male PomcWT, 5-HT2CRCRE, PomcNEO
and Pomc5-HT2CR littermates (n ¼ 4 per genotype). (D) Lorcaserin (4 mg/kg, IP) has no effect on food intake compared to saline in male mice (n ¼ 8). (E) Schematic of lorcaserin
action at ARC Pomc5-HT2CR neurons. Pretreatment with lorcaserin (4 mg/kg, IP) significantly improves glucose tolerance (GTT; 1 g/kg, IP) and insulin tolerance (ITT; 0.75U/kg, IP) in
6 h light cycle fasted (F, J) DIO male PomcWT and (G, K) 5-HT2CR
CRE control mice. These effects are abolished in (H,L) male PomcNEO mice and restored in (I, M) male Pomc5-HT2CR
mice (n ¼ 7e12 per genotype). Scale bar in B, 100 mm applies to all genotypes. *p < 0.05, **p < 0.01, ***p < 0.001 lorcaserin versus saline treatment.
Original ArticleFigure 2L; Figure S2G) but restored in Pomc5-HT2CR mice (treatment F1,
76 ¼ 8.52, p ¼ 0.0046; Figure 2M; Figure S2H). Thus, these results
identify a specific neurochemical mediator of lorcaserin’s glucor-
egulatory effects, brain POMCARC peptides. Moreover, these data
indicate that POMC in a specific subset of ARC neurons expressing 5-
HT2CRs is sufficient to mediate lorcaserin’s glycemic effects.
3.3. MC4RChAT is sufficient to mediate lorcaserin’s glucoregulatory,
but not anorectic, effects
We next examined the receptor target of POMCARC peptides commu-
nicating lorcaserin’s glucoregulatory effect. POMCARC peptides signal
at a family of CNS receptors. Previous reports indicate that brain
inactivation of the melanocortin-4 receptor (MC4R) subtype promotes
hyperphagia, obesity, and a T2D phenotype, attenuates preclinical 5-
HT2CR agonist’s anorectic and glycemic effects, and that MC4Rs1096 MOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elsespecifically within cholinergic neurons play a physiological role in the
regulation of hepatic insulin sensitivity [11,24,25]. Specifically, a
reversible Mc4r knockout mouse (Mc4rNULL) intercrossed with a
Choline acetyltransferase (ChAT; the enzyme that carries out acetyl-
choline production)CRE line to restore Mc4r expression exclusively
within preganglionic sympathetic and parasympathetic neurons
(Mc4rChAT; Figure 3A) revealed that Mc4rNULL mice are hyper-
insulinemic and hyperglycemic and that restoration of the MC4Rs in
ChAT cells inMc4rChAT mice improves hyerinsulinemia, hyperglycemia,
hepatic insulin action, and insulin-induced suppression of hepatic
glucose production, without normalizing hyperphagia [25]. We there-
fore hypothesized that the melanocortin receptor mediating lorcaser-
in’s glycemic effects via POMCARC:5-HT2CR activation is the MC4R, and
the specific subset of MC4Rs is those modulating autonomic outflow
via expression on cholinergic preganglionic neurons (Figure 3B).vier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 3: MC4Rs in cholinergic neurons are sufficient to mediate lorcaserin’s glucoregulatory effects but do not communicate lorcaserin’s anorectic effects. (A) The
reversible Mc4r knockout line (Mc4rNULL) was crossed with a Choline acetyltransferase (ChAT)CRE line to restore Mc4r expression specifically within preganglionic sympathetic and
parasympathetic neurons (Mc4rChAT). (B) Schematic of lorcaserin downstream action at cholinergic MC4Rs. (C, F) Lorcaserin pretreatment (4 mg/kg, IP) improves glucose (GTT; 1 g/
kg; IP) and insulin tolerance (ITT; 0.75 U/kg, IP) in 6 h light cycle fasted DIO WT male mice. (D,G) These effects are abolished in Mc4rNULL male mice and (E, H) restored in Mc4rChAT
male littermates (n ¼ 11e12/genotype). A higher concentration of lorcaserin (7.5 mg/kg, IP) significantly suppresses feeding in (I) WT DIO mice but does not influence feeding in (J)
Mc4rNULL or (K) Mc4rChAT male littermates (n ¼ 7e8/genotype). *p < 0.05, **p < 0.01, ***p < 0.001 lorcaserin versus saline treatment.To directly assess the role of cholinergic MC4Rs in lorcaserin’s gly-
cemic effects, we performed GTTs and ITTs as described above in DIO
Mc4rWT, Mc4rNULL, and Mc4rChAT mice (Figure 3A). Although lorcaserin
(4 mg/kg, IP) improved glycemic control in DIO Mc4rWT mice (GTT F1,
149 ¼ 26.06, p ¼ 0.0001; ITT F1, 98 ¼ 36.86, p ¼ 0.001; Figure 3C,F;
Figure S3A,D), it was ineffective in altering glucose (F1, 119 ¼ 0.07,MOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comp ¼ 0.78; Figure 3D; Figure S3B) or insulin (F1, 84 ¼ 0.12, p ¼ 0.74;
Figure 3G; Figure S3E) tolerance in Mc4rNULL mice. However, lorca-
serin produced a significant improvement in both glucose (treatment
F1, 154 ¼ 5.11, p ¼ 0.025; Figure 3E) and insulin (treatment F1,
127 ¼ 25.92, p ¼ 0.0001; Figure 3H; Figure S3F) tolerance in mice in
which MC4Rs were restored in cholinergic neurons (Mc4rChAT). Notean open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 1097
Original Articlethat although lorcaserin significantly improved glucose tolerance when
analyzed across time (Figure 3E), when analyzed as area under the
curve (Figure S3C), the difference between treatment groups did not
reach statistical significance. This may be a result of methodological
factors (e.g. sample size) or may be due to a smaller role of MC4RChAT
in lorcaserin’s effects on glucose tolerance. These data reveal that CNS
MC4Rs are necessary for lorcaserin’s glucoregulatory effects and that
MC4Rs expressed in cholinergic neurons are sufficient to mediate at
least some of these effects.
We also sought to evaluate the contribution of cholinergic MC4Rs to
lorcaserin’s anorectic effects. As expected, lorcaserin (7.5 mg/kg, IP)
reduced food intake in WT DIO mice (t (14) ¼ 4.1, p ¼ 0.001;
Figure 3I). Like lorcaserin’s glucoregulatory effects, we observed that
downstream activation of CNS MC4Rs is required for lorcaserin to
decrease feeding (t (11) ¼ 1.03, p ¼ 0.34; Figure 3J). However,
restoration of the subset of MC4Rs expressed in cholinergic neurons in
Mc4rChAT mice was not sufficient to restore lorcaserin’s anorectic ef-
fects (t (11) ¼ 1.04, p ¼ 0.32; Figure 3K). These results indicate that
while lorcaserin requires downstream CNS MC4R activation to promote
both glycemic and hypophagic effects, the subpopulation of MC4Rs
mediating these effects is different. Lorcaserin engages non-
cholinergic MC4Rs to elicit its effects on feeding and cholinergic
MC4Rs to improve glucose homeostasis.
3.4. Lorcaserin improves insulin sensitivity, suppresses hepatic
glucose production, and increases glucose disposal, but does not
increase insulin secretion
Having established a melanocortin neurocircuit that is both necessary
and sufficient to mediate the glucoregulatory effects of lorcaserin, we
next sought to characterize the downstream peripheral mechanisms
underpinning lorcaserin’s glycemic effects. Peripheral 5-HT is co-
localized with insulin in pancreatic beta cells and promotes insulin’s
release [32]. We first investigated whether the 5-HT2CR agonist lorca-
serin may affect insulin secretion by performing intravenous glucose
tolerance tests, sampling blood frequently via an indwelling arterial
catheter from freely-moving DIO WT mice following delivery of an
intravenous glucose bolus. Lorcaserin improved glucose clearance (area
under glucose curve) following glucose administration (t (19) ¼ 2.54,
p ¼ 0.01; Figure 4A), but we did not detect any effects of lorcaserin on
acute insulin response to glucose (t (19) ¼ 0.97, p ¼ 0.34; Figure 4B).
The improvement we observe in glucose tolerance in response to lor-
caserin cannot be attributed to increased insulin secretion.
Modeling insulin sensitivity from insulin and glucose data collected
during the intravenous glucose tolerance tests following a bolus of
exogenous insulin delivered 9 min after the glucose bolus, we
observed a non-significant trend for improved insulin sensitivity and
perhaps glucose effectiveness (Figure 4C,D). This may be in part
related to the limitations in sampling frequency and speed and the
sampling volumes required during intravenous glucose tolerance tests
in mice compared with humans. To examine insulin sensitivity in more
detail, we performed insulin clamps with isotope measures of glucose
turnover. In keeping with our previous data consistently showing an
effect of lorcaserin to improve insulin tolerance, DIO WT mice treated
with lorcaserin needed significantly higher rates of dextrose infusion
during clamps to maintain blood glucose (treatment F1, 166 ¼ 93.2,
p ¼ 0.0001; Figure 4E,F). This was explained by both an increase in
glucose disposal (t (7) ¼ 4.50, p < 0.01) and a greater suppression of
hepatic glucose production (t (8) ¼ 9.02, p < 0.01) under clamp
conditions (Figure 4G).
The effects observed on hepatic glucose production are consistent with
previous data showing that under physiological conditions, the central1098 MOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elsemelanocortin pathway plays a role in the suppression of endogenous
glucose production [25,33]. To further examine lorcaserin’s effects on
gluconeogenesis, 6 h fasted DIO WT mice were administered a single
injection of lorcaserin (4 mg/kg, IP) or vehicle 45 min prior to a
tolerance test using the exclusive hepatic gluconeogenic substrate
pyruvate (1.5 g/kg, IP) [34,35]. Whereas pyruvate administration eli-
cited a marked glycemic excursion in saline pretreated mice, lorcaserin
pretreatment completely abolished glucose production upon pyruvate
administration (F1, 98¼ 46.0, p¼ 0.0001; Figure 4H). Taken together,
our data suggest that lorcaserin improves glucose homeostasis acting
centrally via POMCARC signaling to MC4RChAT to increase autonomic
outflow to improve hepatic insulin sensitivity, reduce hepatic glucose
production, and improve glucose disposal.
4. DISCUSSION
T2D is a chronic disease whose prevalence continues to escalate on a
global scale, thereby highlighting the clinical need for a diverse battery
of treatment options. Current frontline medications for T2D target
peripheral tissues to produce improvements in blood glucose and in-
sulin function [36,37]. Here we investigate the potential of targeting 5-
HT2CR circuits within the brain to improve glucoregulatory function and
use specific target manipulations to clarify the neurocircuitry under-
pinning the therapeutic effects.
Lorcaserin is currently licensed for weight loss. In clinical practice in
T2D, weight loss is generally associated with improved glycemic
control making it difficult to separate lorcaserin’s effects on glycemia
from its anorectic actions [38e40]. Using a targeted murine approach,
we demonstrate that lorcaserin improves glycemic control via a neu-
rocircuit discrete from that which mediates its effects on feeding or
body weight.
To specifically probe how this effect may be achieved, we focused on
the homeostatic brain region, the ARC. Within the ARC, POMC neurons
are glucose sensing and have been implicated in the control of insulin
sensitivity [31,41,42]. Specifically, POMCARC deficient mice exhibit
normal blood glucose despite extreme insulin resistance [16,31] due to
elevated glycosuria via reduced sympathetic nerve activity to the
kidney and decreased GLUT2 [31]. Restoration of Pomc expression
only in cells with 5-HT2CRs corrects hyperinsulinemia and insulin
sensitivity [16]. In addition, 5-HT and 5-HT2CR agonists depolarize
POMCARC neurons [14,15,17] and preclinical 5-HT2CR agonists
improve glycemia by acting at 5-HT2CR expressed on POMC neurons
[5,18]. A recent report suggests that this is via action at transient
receptor potential cation 5 (TrpC5) [43]. However, the role of POMC
peptides synthesized within these neurons in lorcaserin’s effects has
not been investigated. We found that lorcaserin’s glucoregulatory ef-
fects were absent in mice lacking hypothalamic Pomc and that
restoration of Pomc in 5-HT2CR-expressing neurons was sufficient to
rescue lorcaserin’s glycemic actions. These data suggest that ARC
POMC5-HT2CR is necessary for the glycemic actions of lorcaserin.
Downstream, POMC peptides primarily act via MC4Rs to elicit
anorectic and glucoregulatory effects [44e47]. In agreement with a
previous report using preclinical 5-HT2CR agonists [30], we observed
that lorcaserin’s glucoregulatory effects were abolished with global
MC4R deficiency in mice. To probe the specific subpopulation of
MC4Rs mediating this effect, we employed a genetic approach. Under
physiological conditions, forebrain single-minded homolog 1 (SIM-1)
MC4Rs have been implicated in feeding behavior [48], whereas
cholinergic MC4Rs mediate melanocortin’s glycemic effects [25].
Consistent with these divergent physiological roles for MC4R sub-
populations, we found that restoration of cholinergic MC4Rs wasvier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 4: Lorcaserin suppresses hepatic gluconeogenesis but does not affect insulin secretion in mouse model of DIO T2D. (A) Blood glucose, (B) plasma insulin, (C)
insulin sensitivity, and (D) glucose effectiveness during frequently sampled intravenous glucose tolerance test (FSIVGTT) following pretreatment with lorcaserin (10 mg/kg, IP) in
male DIO WT mice. (E) Blood glucose, (F) glucose infusion rates (GIR), (G) average disposal rate (RD), average GIR, and average hepatic glucose production (HGP) during
hyperinsulinemic-euglycemic clamps in male DIO WT mice. (H) Pretreatment with lorcaserin (4 mg/kg, IP) improves pyruvate tolerance (PTT; 1.5 g/kg, IP) in 6 h light cycle fasted
DIO WT mice (n ¼ 7e10). *p < 0.05, **p < 0.01, ***p < 0.001 lorcaserin versus saline treatment.
MOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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not feeding. Taken together, these data and our current findings
support a divergence between MC4Rs mediating 5-HT obesity com-
pounds’ effects on feeding and glycemia.
Within the CNS, the two sites of MC4R and ChAT co-expression are
within the preganglionic parasympathetic neurons of the dorsal motor
nucleus of the vagus (DMV) and the pre-ganglionic sympathetic neu-
rons of the intermediolateral nucleus (IML) of the spinal cord. Our
findings are consistent with earlier reports demonstrating a physio-
logical role for cholinergic MC4Rs within the IML in glucose homeo-
stasis [25,33]. Furthermore, pre-clinical 5-HT2CR agonist
administration is associated with an increase in cholinergic neuronal
activation within the IML, POMCARC neurons project to the IML and
MC4R agonists depolarize these same neurons [24,49]. While it cannot
be excluded that cholinergic MC4Rs in the DMV contribute to lorca-
serin’s glucoregulatory effects, physiologically, DMV neurons have
been reported to regulate insulin secretion rather than insulin sensi-
tivity, MC4Rs in the DMV are inhibited by MC4R agonists and do not
appear to be regulated by 5-HT2CR agonists [11,24,25,33]. On bal-
ance, therefore, we postulate that MC4Rs in IML cholinergic neurons
are a critical component of the neural circuit through which lorcaserin
achieves its glycemic effects.
The absence of POMC signaling in PomcNULL mice leads to reduced
sympathetic nerve activity to the kidney and as a result, a down-
regulation of GLUT2, and extreme insulin resistance without elevated
glucose [31]. The proposed effects of lorcaserin via POMCARC to IML
MC4RChAT therefore appear at odds with this phenotype. There could
be many reasons for this apparent discrepancy, such as differential
innervation of IML and DMV cholinergic neurons by 5-HT2CR positive
and negative POMCARC neurons and competing actions of para-
sympathetic and sympathetic autonomic outflow to multiple tissues on
glucose regulation. Alternatively, the difference in results may be due
simply to a difference in physiological effect via a loss (PomcNULL) or
gain (activation through lorcaserin) of function. Further delineation of
the specific subset of MC4RChAT neurons underpinning lorcaserin’s
glycemic effects requires additional investigation.
Our insulin clamp data suggest that the peripheral mechanisms
through which lorcaserin acting via brain autonomic outflow elicits its
anti-diabetic effects include both suppression of hepatic glucose
production and increased glucose uptake but that lorcaserin does not
appear to act by altering insulin secretion. The former is consistent
with earlier reports emphasizing the role of the melanocortin circuit in
the control of peripheral blood glucose via the regulation of hepatic
glucose production, with mice lacking 5-HT2CRs displaying hepatic
insulin resistance and resistance to the anti-diabetic effects of 5-HT2CR
compounds, both of which were restored when 5-HT2CRs were re-
expressed in POMC neurons [5]. MC4Rs specifically in cholinergic
neurons have also been demonstrated to regulate the ability of insulin
to suppress hepatic glucose production [25].5. CONCLUSIONS
In conclusion, T2D is a chronic, debilitating disease with major social,
fiscal, and medical costs. The prevalence of this disease is increasing
markedly, and, despite the emergence of new therapies targeting in-
sulin secretion, insulin action and/or glucose excretion, glycemic
control remains generally sub-optimal, emphasizing the continued
need for new therapeutic options. Given the data supporting a key role
for brain in control of glucose homeostasis [2e9,50] and the reports of
lorcaserin improving glycemic control in patients with T2D with weight1100 MOLECULAR METABOLISM 6 (2017) 1092e1102  2017 The Authors. Published by Elseloss, we utilized a molecular and genetic approach to describe a
POMCARC:5-HT2CR to MC4RChAT glucoregulatory neurocircuit. Moreover,
we report the clinical relevance of this by demonstrating that lorcaserin
acting at the level of the hypothalamus on this POMCARC:5-HT2CR to
MC4RChAT pathway improves peripheral glucose homeostasis in a
mouse model of T2D. There is growing interest in brain control of
peripheral glycemia and the potential for targeting the ARC for therapy
in T2D [51]. Our work suggests that lorcaserin should be investigated
in patients with T2D for blood glucose lowering therapy, in addition to
its already approved licensing for body weight reduction.
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